Cell Panel Screening services
Answer questions in biologically relevant cancer cell types
Leveraging our expertise in screening and receive robust data from high-throughput assays
Rapidly profile your compounds or biologics of interest as single or combination therapies, in an extended assay format. Obtain high quality, actionable data to drive your drug discovery program forward.
OncoSignature™ Long-Term Assay features
- Screen across a diverse, clinically relevant panel or a more focused, tissue-specific panel
- Cell lines grown in vendor-recommended media
- 10 point, 3-fold dilution for single compounds
- 9x9 full dose response matrix for compounds in combination
- 240 h treatment times
- Growth Inhibition measured by ATP levels
Final data report includes
- Growth inhibition measured by ATP levels
- Single agent report - dose response curve, response area, max response, doubling time, IC50 & GI50
- Combination report - dose matrix and model score (i.e., Synergy Score, Loewe Volume Score, Bliss Volume Score)
- Chalice™ and raw data files provided
- Chalice™ viewer software provided
Oncosignature Long-Term Assay (LTA): cell panel screening of slower-acting therapeutics
Slower acting inhibitor classes (PARP and EZH2 inhibitors) showed greater responses in the 10-day LTA (shift to right along X axis, as indicated by arrows) compared to the standard 6-day assay. In contrast, responses for a faster acting therapeutic (WEE1i) were generally similar (points distributed along X=Y line indicating equal response at 6-days and 10-days). Notably, analysis of max response for Olaparib showed that cytotoxic response (>100% growth inhibition) only became evident in the longer duration assay (lower graph).
When time is crucial in developing new drugs, take advantage of the high throughput screening technologies offered in our assay services. From planning and execution to data analysis, we have the expertise to move your project forward. Contact us to discuss your project, one of the team will be in touch within 48 hours.
Long-Term Assay application note
View the data behind the long-term assay service that allows for the profiling of slow acting or epigenetic drugs for 10 days across a clinically relevant panel of 248 cell lines
Read Horizon's CPS blog
Get the latest insights about the drug discovery tools in the cancer cell panel screening field, curated by Horizon's scientists